TRASTUZUMAB BRENGITECAN
UNII 5MHN3G4T8J

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Brengitecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5MHN3G4T8J.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2761149-81-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
5MHN3G4T8J
CAS Registry Number
2761149-81-7
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
TRASTUZUMAB BRENGITECAN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C203071
National Cancer Institute reference terminology for clinical and research data.
INN ID
12677
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Brengitecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TRASTUZUMAB BRENGITECAN

Common Names & Synonyms

IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2) (HUMAN-MUS MUSCULUS MONOCLONAL BL-M07D1 .GAMMA.1-CHAIN), COMPLEX WITH HUMAN-MUS MUSCULUS MONOCLONAL BL-M07D1 .KAPPA.-CHAIN, DIMER, 214'',214''',223,223',229,229',232,232'-OCTAKIS(THIOETHER) WITH (2S)-N-(CARBOXYMETHYL)-2-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-.BETA.-ALANYLGLYCYLGLYCYL-L-PHENYLALANYL-N-(((1S)-2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-1-METHYL-2-OXOETHOXY)METHYL)GLYCINAMIDE
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, EPIDERMAL GROWTH FACTOR RECEPTOR 2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, CONJUGATED TO A CAMPTOTHECIN DERIVATIVE
TRASTUZUMAB BRENGITECAN [INN]

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus